steven
day
named
agenus
chief
medical
officer
lexington
globe
newswire
agenus
nasdaq
agen
company
extensive
pipeline
checkpoint
antibodies
cell
therapies
adjuvants
vaccines
designed
activate
immune
response
cancers
infections
today
announced
appointment
steven
day
md
chief
medical
officer
welcome
day
take
lead
candidates
bla
advance
several
novel
therapies
advanced
phases
clinical
development
said
garo
armen
phd
chairman
ceo
agenus
dr
day
pioneering
record
development
therapies
cancer
treatments
invaluable
implement
rapid
innovative
clinical
trials
day
leadership
field
spans
three
decades
part
small
group
investigators
treat
first
patients
first
checkpoint
antibody
molecule
ipilimumab
presented
seminal
data
plenary
session
asco
demonstrated
curative
potential
long
durable
survival
benefit
patients
metastatic
melanoma
data
led
fda
approval
ipilimumab
following
year
day
presenting
clinical
outcomes
molecule
sitc
starting
november
agenus
innovative
company
field
platforms
capabilities
produced
outstanding
pipeline
clinical
preclinical
agents
excited
join
agenus
pathbreaking
scientific
clinical
team
share
bold
vision
future
day
said
together
accelerate
optimal
combination
treatments
patients
cancer
transformative
period
company
history
thrilled
join
day
principal
investigator
clinical
trials
including
international
pivotal
trials
held
leadership
roles
currently
serves
executive
director
john
wayne
cancer
institute
cancer
clinics
providence
john
health
center
director
melanoma
cutaneous
oncology
research
center
receiving
ba
chemistry
williams
college
day
selected
visiting
scholar
philosophy
medical
ethics
oxford
university
received
md
completed
internal
medicine
residency
johns
hopkins
university
school
medicine
followed
medical
oncology
bone
marrow
transplant
fellowship
dana
farber
harvard
cancer
center
agenus
agenus
company
focused
discovery
development
therapies
engage
body
immune
system
fight
cancer
company
vision
expand
patient
populations
benefiting
cancer
immunotherapy
pursuing
combination
approaches
leverage
broad
repertoire
antibody
therapeutics
adoptive
cell
therapies
agentus
therapeutics
subsidiary
proprietary
cancer
vaccine
platforms
company
equipped
suite
antibody
discovery
platforms
gmp
manufacturing
facility
capacity
support
clinical
programs
agenus
headquartered
lexington
information
please
visit
twitter
handle
information
may
important
investors
routinely
posted
website
twitter
statements
press
release
contains
statements
made
pursuant
safe
harbor
provisions
federal
securities
laws
including
statements
regarding
anticipated
therapeutic
benefit
clinical
development
regulatory
plans
timelines
statements
subject
risks
uncertainties
could
cause
actual
results
differ
materially
risks
uncertainties
include
among
others
factors
described
risk
factors
section
recent
quarterly
report
form
annual
report
form
filed
securities
exchange
commission
agenus
cautions
investors
place
considerable
reliance
statements
contained
release
statements
speak
date
press
release
agenus
undertakes
obligation
update
revise
statements
extent
required
law
statements
expressly
qualified
entirety
cautionary
statement
